CENTRIC includes patients with newly diagnosed glioblastoma
and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter status.
People who undergo repeated surgeries to remove glioblastomas
- the most aggressive and deadliest type of brain tumors - may survive longer than those who have a one-time operation, new Johns Hopkins research suggests.
is the most common brain tumour, accounting for 12 - 15% of intracranial neoplasms and 50 - 60% of astrocytic tumours.
multiforme primario frecuentemente muestra amplificacion, aumento de la expresion o ambos, del receptor del factor de crecimiento epidermico (Epidermal Growth Factor Receptor, EGFR), mutaciones de PTEN (delecion del cromosoma 10 para el homologo de la fosfatasa y la tensina) y perdida parcial o completa del cromosoma 10.
To study the potential of glioblastoma
exosomes as markers of a tumor's genetic makeup, the research team analyzed tumor tissue and blood serum from 25 glioblastoma
patients and were able both to find tumor exosomes and to identify, in some samples, a mutation in the epidermal growth factor receptor (EGFR) gene that characterizes a tumor subtype.
Patients with recurrent glioblastoma
whose tumor progresses despite radiation treatment and chemotherapy do not have many options," Engelhard said.
The calcium-permeable receptors may be a therapeutic target in treating brain tumors and the introduction of a gene or chemical antagonist that blocks them is expected to become an effective glioblastoma
treatment, it said.
Given the poor responsiveness of most brain tumors, and particularly of glioblastomas
, to chemotherapy and radiation, and the substantial impairment of cognitive function associated with such treatments, perhaps it is time to consider whether such patients ought to be offered the possibility of trying experimental approaches before traditional ones are use," Noble wrote.
NantKwest announced that the first patient has been dosed in a first-in-human, Phase I clinical study in glioblastoma
There is an ongoing debate regarding role of surgery for recurrent glioblastoma
M2 EQUITYBITES-November 28, 2017-INSIGHTEC wins US FDA approval to initiate first study of Exablate Neuro to open blood-brain barrier in glioblastoma
M2 PHARMA-November 28, 2017-INSIGHTEC wins US FDA approval to initiate first study of Exablate Neuro to open blood-brain barrier in glioblastoma